Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018

– First oral presentation of the results of OASIS-2, the Phase 3 omadacycline oral-only study in ABSSSI
– Poster presentations include new microbiology analyses from OASIS-2
BOSTON, April 12, 2018 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that data from its omadacycline clinical and microbiology programs will be presented at the annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases, ECCMID 2018, to be held April 21 – 24 in Madrid, Spain. The data continue to highlight the compelling efficacy and safety profile of omadacycline, an investigational once-daily oral and intravenous (IV) monotherapy antibiotic, for the tr…


Leave a Reply

Your email address will not be published.